EyePoint Completes Third Safety Review for Duravyu
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 14 2026
0mins
EyePoint announced the independent data safety monitoring committee completed its third scheduled review of the company's pivotal Phase 3 program evaluating Duravyu for wet age-related macular degeneration, recommending both the LUGANO and LUCIA trials continue as planned with no protocol modifications. Interim masked safety data show a continued favorable safety profile, consistent with safety observed in over 190 patients across four completed clinical trials. As of May 2, all active patients in the treatment arm have reached the Week 32 visit, receiving their second DURAVYU dose, with over 35% also receiving a third planned dose at Week 56. LUGANO topline data is on track for mid-2026, with LUCIA to follow shortly after; this is the last anticipated committee review ahead of topline data. "Safety is paramount in retinal disease therapies, and receiving three consecutive positive DSMC recommendations to continue our Phase 3 wet AMD trials without modification reflects the consistency of DURAVYU's safety profile and the rigor of our Phase 3 wet AMD program design," said Ramiro Ribeiro, chief medical officer.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EYPT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EYPT
Wall Street analysts forecast EYPT stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 14.440
Low
20.00
Averages
31.50
High
43.00
Current: 14.440
Low
20.00
Averages
31.50
High
43.00
About EYPT
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ADMA Biologics Shows Promising Profitability Outlook
- Profitability Growth: ADMA Biologics reported a net income of $407 million in Q1, reflecting a 22% year-over-year increase, indicating sustained profitability that is expected to enhance the company's competitive edge in the biopharmaceutical market.
- Significant Market Potential: Currently capturing only 4% of its total addressable market, ADMA is positioned for substantial growth, with the market projected to expand at a compound annual growth rate of 10% through 2033, suggesting significant revenue growth opportunities ahead.
- Optimistic Product Outlook: EyePoint Pharmaceuticals is on track to announce results from clinical trials for Duravyu, targeting wet age-related macular degeneration, with a market opportunity exceeding $15 billion, which could significantly elevate the company's market position if approved.
- Investment Risks and Rewards: Viking Therapeutics has an average price target 146% above its current share price, and while it remains unprofitable, its potential in obesity drug development makes it a focal point for investors, despite the inherent investment risks.
See More
SpaceX's $2 Trillion Valuation Faces Significant Hurdles Ahead
- SpaceX Valuation Analysis: Despite SpaceX's market cap hovering around $2 trillion, the company generated only $18.7 billion in revenue last year and posted a nearly $5 billion loss, indicating the fragility of its high valuation and making a doubling of its stock price over the next two to three years highly unlikely.
- ADMA Biologics Profit Growth: ADMA Biologics reported a net income of $407 million in Q1, up 22% year-over-year, with its flagship product Asceniv accounting for approximately 86% of total revenue, showcasing strong growth potential in the plasma-derived immunoglobulin market.
- EyePoint Pharmaceuticals Clinical Prospects: EyePoint Pharmaceuticals expects to announce top-line results for Duravyu soon, targeting wet age-related macular degeneration with a market opportunity exceeding $15 billion; analysts are overwhelmingly bullish, with a consensus price target 165% higher than the current share price.
- Viking Therapeutics Potential Breakthrough: Viking Therapeutics is conducting two Phase 3 trials for VK2735, and although it is currently unprofitable, its pipeline includes multiple promising therapies, with the average price target for the stock indicating a potential upside of 146%, reflecting significant growth potential.
See More
EyePoint Grants Stock Options to New Employees
- Stock Option Grant: EyePoint, Inc. granted stock options for 39,700 shares to three new employees on June 15, 2026, with an exercise price of $12.08 per share, aimed at attracting talent and enhancing employee loyalty.
- Incentive Plan Compliance: The grants comply with NASDAQ Listing Rule 5635(c)(4) and were approved by the Compensation Committee, reflecting the company's commitment to new hires and its long-term strategic vision.
- Vesting Arrangement: The stock options will vest over four years, with 25% vesting on the first anniversary and the remainder in monthly installments, ensuring continued employee contributions during their tenure at EyePoint.
- Product Development Progress: EyePoint's lead product, DURAVYU™, is undergoing Phase 3 clinical trials, with topline data for wet age-related macular degeneration (wet AMD) expected in mid-2026, further solidifying the company's market position in ophthalmic treatments.
See More
EyePoint to Participate in Upcoming Healthcare Conferences
- Conference Participation: EyePoint management will participate in several key healthcare conferences, including the Stifel 2026 Virtual Ophthalmology Forum on May 26, the Jefferies Global Healthcare Conference on June 3, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, showcasing their latest advancements in retinal disease treatments.
- Product Development Progress: EyePoint's lead product, DURAVYU™, is currently undergoing Phase 3 pivotal trials for wet age-related macular degeneration and diabetic macular edema, with topline data expected in mid-2026 for wet AMD, which could significantly enhance the company's market position if successful.
- Technological Innovation: DURAVYU™ combines the selective tyrosine kinase inhibitor vorolanib with next-generation bioerodible Durasert E™ technology to provide sustained therapeutic effects, aiming to improve patient quality of life and demonstrating EyePoint's innovative capabilities in retinal disease treatment.
- Market Positioning and Strategy: EyePoint is committed to partnering with the retina community to enhance patient lives while creating long-term value, having approved four drugs over three decades and treated tens of thousands of eyes, showcasing its leadership and influence in the industry.
See More
EyePoint Grants Stock Options to New Employees as Inducement Awards
- Stock Option Grant: EyePoint, Inc. granted a total of 158,100 non-statutory stock options to eight new employees on May 15, 2026, as inducement awards to attract talent and enhance employee loyalty, in accordance with NASDAQ Listing Rule 5635(c)(4).
- Exercise Price Set: The options have an exercise price of $12.35 per share, which is the closing price of EyePoint's stock on the grant date, ensuring that potential employee gains are closely tied to the company's performance over the next four years.
- Vesting Arrangement: The options vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly, a structure that not only incentivizes long-term employee retention but also enhances overall operational efficiency for the company.
- R&D Progress: EyePoint is conducting Phase 3 clinical trials for DURAVYU™, targeting serious retinal diseases, with topline data for wet age-related macular degeneration (wet AMD) expected in mid-2026, which could significantly enhance the company's market competitiveness.
See More
EyePoint (EYPT) Q1 2026 Earnings Transcript
See More
ADMA Biologics Shows Promising Profitability Outlook
- Profitability Growth: ADMA Biologics reported a net income of $407 million in Q1, reflecting a 22% year-over-year increase, indicating sustained profitability that is expected to enhance the company's competitive edge in the biopharmaceutical market.
- Significant Market Potential: Currently capturing only 4% of its total addressable market, ADMA is positioned for substantial growth, with the market projected to expand at a compound annual growth rate of 10% through 2033, suggesting significant revenue growth opportunities ahead.
- Optimistic Product Outlook: EyePoint Pharmaceuticals is on track to announce results from clinical trials for Duravyu, targeting wet age-related macular degeneration, with a market opportunity exceeding $15 billion, which could significantly elevate the company's market position if approved.
- Investment Risks and Rewards: Viking Therapeutics has an average price target 146% above its current share price, and while it remains unprofitable, its potential in obesity drug development makes it a focal point for investors, despite the inherent investment risks.
See More
SpaceX's $2 Trillion Valuation Faces Significant Hurdles Ahead
- SpaceX Valuation Analysis: Despite SpaceX's market cap hovering around $2 trillion, the company generated only $18.7 billion in revenue last year and posted a nearly $5 billion loss, indicating the fragility of its high valuation and making a doubling of its stock price over the next two to three years highly unlikely.
- ADMA Biologics Profit Growth: ADMA Biologics reported a net income of $407 million in Q1, up 22% year-over-year, with its flagship product Asceniv accounting for approximately 86% of total revenue, showcasing strong growth potential in the plasma-derived immunoglobulin market.
- EyePoint Pharmaceuticals Clinical Prospects: EyePoint Pharmaceuticals expects to announce top-line results for Duravyu soon, targeting wet age-related macular degeneration with a market opportunity exceeding $15 billion; analysts are overwhelmingly bullish, with a consensus price target 165% higher than the current share price.
- Viking Therapeutics Potential Breakthrough: Viking Therapeutics is conducting two Phase 3 trials for VK2735, and although it is currently unprofitable, its pipeline includes multiple promising therapies, with the average price target for the stock indicating a potential upside of 146%, reflecting significant growth potential.
See More
EyePoint Grants Stock Options to New Employees
- Stock Option Grant: EyePoint, Inc. granted stock options for 39,700 shares to three new employees on June 15, 2026, with an exercise price of $12.08 per share, aimed at attracting talent and enhancing employee loyalty.
- Incentive Plan Compliance: The grants comply with NASDAQ Listing Rule 5635(c)(4) and were approved by the Compensation Committee, reflecting the company's commitment to new hires and its long-term strategic vision.
- Vesting Arrangement: The stock options will vest over four years, with 25% vesting on the first anniversary and the remainder in monthly installments, ensuring continued employee contributions during their tenure at EyePoint.
- Product Development Progress: EyePoint's lead product, DURAVYU™, is undergoing Phase 3 clinical trials, with topline data for wet age-related macular degeneration (wet AMD) expected in mid-2026, further solidifying the company's market position in ophthalmic treatments.
See More
EyePoint to Participate in Upcoming Healthcare Conferences
- Conference Participation: EyePoint management will participate in several key healthcare conferences, including the Stifel 2026 Virtual Ophthalmology Forum on May 26, the Jefferies Global Healthcare Conference on June 3, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, showcasing their latest advancements in retinal disease treatments.
- Product Development Progress: EyePoint's lead product, DURAVYU™, is currently undergoing Phase 3 pivotal trials for wet age-related macular degeneration and diabetic macular edema, with topline data expected in mid-2026 for wet AMD, which could significantly enhance the company's market position if successful.
- Technological Innovation: DURAVYU™ combines the selective tyrosine kinase inhibitor vorolanib with next-generation bioerodible Durasert E™ technology to provide sustained therapeutic effects, aiming to improve patient quality of life and demonstrating EyePoint's innovative capabilities in retinal disease treatment.
- Market Positioning and Strategy: EyePoint is committed to partnering with the retina community to enhance patient lives while creating long-term value, having approved four drugs over three decades and treated tens of thousands of eyes, showcasing its leadership and influence in the industry.
See More
EyePoint Grants Stock Options to New Employees as Inducement Awards
- Stock Option Grant: EyePoint, Inc. granted a total of 158,100 non-statutory stock options to eight new employees on May 15, 2026, as inducement awards to attract talent and enhance employee loyalty, in accordance with NASDAQ Listing Rule 5635(c)(4).
- Exercise Price Set: The options have an exercise price of $12.35 per share, which is the closing price of EyePoint's stock on the grant date, ensuring that potential employee gains are closely tied to the company's performance over the next four years.
- Vesting Arrangement: The options vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly, a structure that not only incentivizes long-term employee retention but also enhances overall operational efficiency for the company.
- R&D Progress: EyePoint is conducting Phase 3 clinical trials for DURAVYU™, targeting serious retinal diseases, with topline data for wet age-related macular degeneration (wet AMD) expected in mid-2026, which could significantly enhance the company's market competitiveness.
See More
EyePoint (EYPT) Q1 2026 Earnings Transcript
See More
